P
Peter M. Hoogerbrugge
Researcher at Radboud University Nijmegen
Publications - 158
Citations - 6588
Peter M. Hoogerbrugge is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Leukemia & Cancer. The author has an hindex of 42, co-authored 151 publications receiving 5709 citations. Previous affiliations of Peter M. Hoogerbrugge include Boston Children's Hospital & Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Skeletal muscle ultrasound: correlation between fibrous tissue and echo intensity.
Sigrid Pillen,Ramon O. Tak,Machiel J. Zwarts,Martin Lammens,Kiek Verrijp,Ilse M.P. Arts,Jeroen van der Laak,Peter M. Hoogerbrugge,Baziel G.M. van Engelen,Aad Verrips +9 more
TL;DR: The high correlation between interstitial fibrous tissue and EI makes ultrasound a reliable method to determine severity of structural muscle changes, and it is concluded that Fibrous tissue causes increased muscle EI.
Journal ArticleDOI
High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.
Roland P. Kuiper,Eric F.P.M. Schoenmakers,S.V. van Reijmersdal,Jayne Y. Hehir-Kwa,A. Geurts van Kessel,F.N. van Leeuwen,Peter M. Hoogerbrugge +6 more
TL;DR: The fact that the authors frequently encountered multiple lesions affecting genes involved in cell cycle regulation and B-cell differentiation strongly suggests that both these processes need to be targeted independently and simultaneously to trigger ALL development.
Journal ArticleDOI
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Gordana Jovic,Jane Hook,Mark Krailo,Mark C. Gebhardt,Zsuzsanna Papai,James O. Meyer,Helen Nadel,R. Lor Randall,Claudia Deffenbaugh,Rajaram Nagarajan,Bernadette Brennan,G. Douglas Letson,Lisa A. Teot,Allen M. Goorin,Daniel Baumhoer,Leo Kager,Mathias Werner,Ching C. Lau,Kirsten Sundby Hall,Hans Gelderblom,Paul A. Meyers,Richard Gorlick,Reinhard Windhager,Knut Helmke,Mikael Eriksson,Peter M. Hoogerbrugge,Paula J. Schomberg,Per-Ulf Tunn,Thomas Kühne,Heribert Jürgens,Henk van den Berg,Tom Böhling,Susan Picton,Marleen Renard,Peter Reichardt,Joachim Gerss,Trude Butterfass-Bahloul,Carol D. Morris,Pancras C.W. Hogendoorn,Beatrice Seddon,Gabriele Calaminus,Maria Michelagnoli,Catharina Dhooge,Matthew R. Sydes,Mark L. Bernstein +48 more
TL;DR: Investigation of maintenance therapy with pegylated interferon alfa-2b in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy found that MAP plus IFN-α-2B was not statistically different from MAP alone.
Journal ArticleDOI
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
Arian van der Veer,Esmé Waanders,Rob Pieters,Marieke E. Willemse,Simon V. van Reijmersdal,Lisa J. Russell,Christine J. Harrison,William E. Evans,Vincent H.J. van der Velden,Peter M. Hoogerbrugge,Frank N. van Leeuwen,Gabriele Escherich,Martin A. Horstmann,Leila Mohammadi Khankahdani,Dimitris Rizopoulos,Hester A. de Groot-Kruseman,Edwin Sonneveld,Roland P. Kuiper,Monique L. den Boer +18 more
TL;DR: The BCR-ABL1-like signature and an IKZF1 deletion, but not CRLF2-high, are prognostic factors and are clinically of importance to identify high-risk patients who require more intensive and/or alternative therapies.
Journal ArticleDOI
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Roland P. Kuiper,Esmé Waanders,V H J van der Velden,S.V. van Reijmersdal,Ramprasath Venkatachalam,Blanca Scheijen,E Sonneveld,J. J. M. Van Dongen,Anjo J.P. Veerman,F.N. van Leeuwen,A. Geurts van Kessel,Peter M. Hoogerbrugge +11 more
TL;DR: It is revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates and serves as one of the strongest predictors of relapse at the time of diagnosis with high potential for future risk stratification.